We realize it’s important to bring together, through partnership and collaboration, diverse scientific talent and capabilities to find the best possible outcomes for the people we serve.

ALAN PALKOWITZ, PH.D.
Vice President, Discovery Chemistry
For scientists.
By scientists.

Together we can make a much greater difference than any of us could alone. That’s why Lilly Open Innovation Drug Discovery (OIDD) is focused on the collaborative efforts that push science forward.

Lilly OIDD was created for scientists, by scientists. We engage external investigators like you in a hypothesis-driven approach to early drug discovery. We give you access to the same tools and expertise available to our scientists to design, test, and make new molecules. You retain complete control of your intellectual property while still benefiting from the proprietary analysis we provide. And, you can use our molecules to test your own biological hypotheses. So you can keep asking “what if” and explore the possibilities.

**WHAT’S IN IT FOR YOU?**
- Ownership of your submissions and publication-quality data
- Access to our secure platform for on-demand status information and strict confidentiality to protect your intellectual property
- Cutting-edge computational tools, in vitro biological assays, quality-designed privileged molecular libraries and synthetic technologies
- The ability to move your science forward by engaging in iterative experimentation
- Multiple opportunities for your institution to collaborate with Lilly scientists who will engage with your science
- Control of the process—the decision to take the next step is always yours

**EMERGING BIOLOGY**
Our Emerging Biology Offering provides access to our privileged compound libraries. You can interrogate your biological assays using Lilly-provided chemical matter to test your hypotheses in your laboratory. Biological results generated are shared by both parties, and Lilly discloses the structures of potentially interesting compounds from the library. The findings may form the basis for further collaboration, but you control the results and are free to publish if you so desire.

**DESIGN**
We make available a variety of in silico design tools that give investigators the power to design molecules with desirable drug-like properties that engage specific biological targets. You get access to sophisticated computational workflows in a private, secure environment in the cloud. Your ideas are never shared with Lilly or Lilly systems without your consent.

**SCREENING**
Lilly continues to invest significant resources into the development of in vitro screening modules within therapeutic areas of long-standing strategic interest. By making these proprietary assay modules available to external investigators, we’re providing in-kind research capabilities for evaluation and characterization of your compounds. And, you and your institution retain ownership of all generated data and associated intellectual property rights.

**ANIMAL HEALTH**
Elanco Animal Health, a division of Eli Lilly and Company, offers you the opportunity to evaluate your compound library for efficacy in our proprietary whole organism screens. The process works the same for both Lilly and Elanco biological screens. Findings may form the basis for collaboration on new therapeutic modes of action or receptor targets in parasitology and could help us identify new scientific breakthroughs.

**SYNTHESIS**
Synthesis offers you the opportunity to prepare compounds remotely in our Automated Synthesis Laboratory. You not only get access to this state-of-the-art equipment, but also to a portion of synthesized material and associated in vitro data from screening. All proposed compound structures remain confidential until you select them for synthesis.

**COMPOUND ACQUISITION**
Our program acquires compounds of interest from those submitted through OIDD to help us add structural diversity to our existing compound collection. Submitters can potentially earn money for their research while also helping Lilly expand the base of compounds we can study in an effort to advance the science that leads to new drug discovery.

**NEGLECTED AND TROPICAL DISEASES**
We have standing agreements with global partner agencies that support non-profit research in neglected and tropical diseases. If one of our partners identifies your compound as a molecule of interest, you may opt to engage directly with that partner.